Literature DB >> 22569341

Soluble urokinase receptor and focal segmental glomerulosclerosis.

Jochen Reiser1, Changli Wei, James Tumlin.   

Abstract

PURPOSE OF REVIEW: We discuss recent work on the pathogenetic mechanism of focal segmental glomerulosclerosis (FSGS) and its relationship to soluble urokinase receptor (suPAR). RECENT
FINDINGS: Primary FSGS can affect both children and adults. The disease can recur after kidney transplantation suggesting the involvement of a causative circulating factor. Recent work suggests that approximately two-thirds of FSGS patients have elevated levels of serum suPAR, which confers risk to both native and posttransplant FSGS.
SUMMARY: Future studies that are geared to understand the clinical implications of high suPAR levels in native FSGS as well as in the pretransplant and posttransplant setting will allow for better patient risk stratification and more targeted treatment options.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569341     DOI: 10.1097/MNH.0b013e328354a681

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  16 in total

1.  Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.

Authors:  Mukut Sharma; Jianping Zhou; Jean-François Gauchat; Ram Sharma; Ellen T McCarthy; Tarak Srivastava; Virginia J Savin
Journal:  Transl Res       Date:  2015-03-16       Impact factor: 7.012

Review 2.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

3.  Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.

Authors:  Carlos R Franco Palacios; John C Lieske; Hani M Wadei; Andrew D Rule; Fernando C Fervenza; Nikolay Voskoboev; Vesna D Garovic; Ladan Zand; Mark D Stegall; Fernando G Cosio; Hatem Amer
Journal:  Transplantation       Date:  2013-08-27       Impact factor: 4.939

4.  Nephronectin (NPNT) and the prediction of nephrotic syndrome response to steroid treatment.

Authors:  Mona Mohamed Watany; Hemat El-Sayed El-Horany
Journal:  Eur J Hum Genet       Date:  2018-06-11       Impact factor: 4.246

Review 5.  Integrins in kidney disease.

Authors:  Ambra Pozzi; Roy Zent
Journal:  J Am Soc Nephrol       Date:  2013-05-02       Impact factor: 10.121

6.  Circulating suPAR in two cohorts of primary FSGS.

Authors:  Changli Wei; Howard Trachtman; Jing Li; Chuanhui Dong; Aaron L Friedman; Jennifer J Gassman; June L McMahan; Milena Radeva; Karsten M Heil; Agnes Trautmann; Ali Anarat; Sevinc Emre; Gian M Ghiggeri; Fatih Ozaltin; Dieter Haffner; Debbie S Gipson; Frederick Kaskel; Dagmar-Christiane Fischer; Franz Schaefer; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2012-11-08       Impact factor: 10.121

7.  1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.

Authors:  Jianchao Ma; Bin Zhang; Shuangxin Liu; Shaoting Xie; Yun Yang; Juan Ma; Yujun Deng; Wenjian Wang; Lixia Xu; Ruizhao Li; Li Zhang; Chunping Yu; Wei Shi
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 8.  Renal biopsy: use of biomarkers as a tool for the diagnosis of focal segmental glomerulosclerosis.

Authors:  Crislaine Aparecida da Silva; Mariana Molinar Mauad Cintra; Eliângela de Castro Côbo; Marcos Vinícius da Silva; Fabiano Bichuette Custódio; Rosana Rosa Miranda Corrêa; Lúcio Roberto Castellano; Marlene Antônia dos Reis; Juliana Reis Machado
Journal:  Dis Markers       Date:  2014-02-25       Impact factor: 3.434

Review 9.  Issues in solid-organ transplantation in children: translational research from bench to bedside.

Authors:  Steven E Lipshultz; Jayanthi J Chandar; Paolo G Rusconi; Alessia Fornoni; Carolyn L Abitbol; George W Burke; Gaston E Zilleruelo; Si M Pham; Elena E Perez; Ruchika Karnik; Juanita A Hunter; Danielle D Dauphin; James D Wilkinson
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

10.  Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Authors:  Massimo Alfano; Paola Cinque; Guido Giusti; Silvia Proietti; Manuela Nebuloni; Silvio Danese; Silvia D'Alessio; Marco Genua; Federica Portale; Manuela Lo Porto; Pravin C Singhal; Maria Pia Rastaldi; Moin A Saleem; Domenico Mavilio; Joanna Mikulak
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.